NEW YORK (GenomeWeb) – Inform Genomics today announced it has raised $2.6 million in a private placement of preferred stock. 

The firm did not say who the participants in the financing were. It said that the proceeds will go toward advancing its lead programs to support cancer care, including OnPart and HSCT/Mucositis; the development of a proprietary analytic platform; and for general corporate uses, including patent filings and working capital. 

OnPart and MSCT/Mucositis are platforms for predicting a patient's risk for developing common chemotherapy-related side effects. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Nature News writes that researchers are still wrangling over the role of the p-value.

In Nature this week: paternal age associated with de novo mutations in children, and more.